Glycaemic and T-lymphocyte markers after Vitamin D3(VD) treatment in type 1 diabetes mellitus (T1D)
D Bogdanou, M Penna-Martinez, TL Chung, Y Moran-Auth, J Wehrle, C Brehm, S Huenecke, E Herrmann, U Koehl, K Badenhoop · Diabetologie und Stoffwechsel · 2014 · Heft 05
Bibliografische Angaben
Zusammenfassung
T1D develops after immune mediated destruction of insulin-producing β-cells. Hereby the dysregulation of adaptive immunity, in particular T-helper (Th) and regulatory cells (Tregs), plays the major role. VD insufficiency is an established risk factor and VD-supplementation in infantry is associated with reduced T1D incidence. VD-therapy in new onset, as well as chronic T1D may have beneficial immune and metabolic effects. Aim: We investigated a 3-months VD-therapy (v) of 4.000IU/d compared to 3-months placebo (p) in T1D. Methods: T1D patients (n = 39; 19 women, 20 men) participated in a placebo-controlled, rando…
